Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT04112238 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma

CNSctDNA
Start date: August 29, 2019
Phase:
Study type: Observational [Patient Registry]

The study is a prospective clinical study which investigates the use of new diagnostic methods to localize aggressive lymphoma involving the central nervous system(CNS). By measuring cell-free tumor DNA and metabolomics in cerebrospinal fluid and blood in patients with systemic Diffuse Large B-cell Lymphoma the investigators aim to improve the diagnostic certainty of an impending relapse of lymphoma in CNS.

NCT ID: NCT04110301 Recruiting - Clinical trials for Follicular Lymphoma and Marginal Zone Lymphoma

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Start date: November 28, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).

NCT ID: NCT04109872 Recruiting - Clinical trials for Mantle Cell Lymphoma

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

Start date: September 15, 2018
Phase:
Study type: Observational

This is a multicentric, observational and retrospective study of the use of lenalidomide in patients with relapsed or refractory mantle cell lymphoma that are included in the RRMCL spanish program. The lenalidomide effectiveness and tolerability data will be retrospectely collected until the 30 of April 2018.

NCT ID: NCT04108325 Recruiting - Clinical trials for Relapsed or Refractory Peripheral T-Cell Lymphoma

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Start date: March 30, 2020
Phase: Phase 1
Study type: Interventional

A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T cell lymphoma.

NCT ID: NCT04107285 Recruiting - Clinical trials for Lymphoma Receiving CAR-T Therapy

Looking at Brain Changes in People With Lymphoma Receiving CAR-T Therapy

Start date: September 25, 2019
Phase:
Study type: Observational

The purpose of this study is to learn about possible changes in cognitive (mental) abilities, such as memory skills and concentration, and in brain anatomy (structure) and function, in people with lymphoma receiving CAR-T therapy.

NCT ID: NCT04104776 Recruiting - Endometrial Cancer Clinical Trials

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Start date: September 18, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.

NCT ID: NCT04099966 Recruiting - Sickle Cell Disease Clinical Trials

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

NCT ID: NCT04097067 Recruiting - Clinical trials for Marginal Zone Lymphoma (Gastric or Duodenal)

ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

This trial studies the effectivity of low-dose radiation therapy with 10x2Gy for the treatment of patients with stage I-II stomach or duodenal Lymphoma (Marginal Zone or Follicular)

NCT ID: NCT04096690 Recruiting - Clinical trials for Nasal Type Extranodal NK/T-Cell Lymphoma

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

Start date: September 10, 2019
Phase: Phase 2
Study type: Interventional

This open-label, single arm study will evaluate the efficacy and safety of anti-PD-1 antibody in combination with pegaspargase in treatment of newly diagnosed advanced stage NK/T-cell lymphoma.

NCT ID: NCT04094610 Recruiting - Lymphoma Clinical Trials

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Start date: March 12, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.